

Pemetrexed disodium for the treatment of malignant pleural mesothelioma – additional economic analysis

In addition to the addendum to the Assessment Report provided by the Assessment Group, additional economic analysis in relation to the manufacturer's indirect comparison (model 2) was undertaken by the NICE project team. The purpose of this analysis was to calculate the incremental cost effectiveness of pemetrexed + cisplatin versus MVP and vinorelbine when resource use estimates for the comparators were taken from the literature instead of the manufacturer's market research survey and when more favourable survival assumptions were used.

The results of this analysis were presented at the Committee meeting of 7th March 2006.

Pemetrexed + cisplatin versus MVP

	Pemetrexed + cisplatin (FS)	MVP	Incremental
Costs	£11,410	£2,368	£9,042
QALYs	0.83	0.68	0.15
ICER	-	-	£60,280¹

- Assumes 3 cycles of MVP. This is the median number of cycles reported by both published trials, Middleton et al (1998) and Andreopoulou et al (2004).
- Assumes performance status adjusted mean survival of 11.8 months for MVP (Addendum to the Assessment Report paragraph 5.1), discounted according to methodology used in the manufacturer's submission

Pemetrexed + cisplatin versus vinorelbine

	Pemetrexed + cisplatin (FS)	Vinorelbine	Incremental
Costs	£11,410	£3,615	£7,795
QALYs	0.83	0.74	0.09
ICER	-	-	£86,611

- The weighted average cost (calculated according to the methodology used in the manufacturer's submission and based on frequency of different treatment regimes reported by the manufacturer) assumes 2 cycles of vinorelbine monotherapy as reported by Steele et al (2000). Resource use assumptions are unchanged for vinorelbine + cisplatin / carboplatin as

¹ ICER presented at Committee meeting was £60,346 due to arithmetic error (corrected in this document)

numbers of cycles used in the literature are consistent with the manufacturer's market research survey.

- Assumes mean survival of 10.6 months for MVP as reported by Steele et al (2000), discounted according to the methodology used in the manufacturer's submission.

Kate Burslem
NICE Technical Lead
21st March 2006